$1.89
Live
2.91%
Downside
Day's Volatility :2.91%
Upside
0.0%
17.99%
Downside
52 Weeks Volatility :64.93%
Upside
57.24%
Period | Lixte Biotechnology Holdings Inc | Index (Russel 2000) |
---|---|---|
3 Months | -18.19% | 0.0% |
6 Months | -43.59% | 0.0% |
1 Year | -11.69% | 0.0% |
3 Years | -89.84% | -23.0% |
Market Capitalization | 4.3M |
Book Value | -$0.56 |
Earnings Per Share (EPS) | -1.72 |
PEG Ratio | 0.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -87.33% |
Return On Equity TTM | -163.33% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
Diluted Eps TTM | -1.72 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Sell
Neutral
Buy
Lixte Biotechnology Holdings Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Lixte Biotechnology Holdings Inc | 2.71% | -43.59% | -11.69% | -89.84% | -94.95% |
Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Lixte Biotechnology Holdings Inc | NA | NA | 0.0 | 0.0 | -1.63 | -0.87 | NA | -0.56 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Lixte Biotechnology Holdings Inc | NA | $4.3M | -94.95% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Lixte Biotechnology Holdings Inc
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 103.2%
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 134.6%
HighTower Advisors, LLC
FNY Investment Advisers, LLC
Ethos Financial Group LLC
Tower Research Capital LLC
UBS Group AG
Bank of America Corp
lixte biotechnology holdings, inc. (lixte) is a clinical-stage public (lixt) pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer. lixte has identified molecular signaling pathways altered in disease states and designed compounds that can safely target them in animal models. the current drug portfolio includes inhibitors of protein phosphatases that are critical to cell division and dna damage repair and inhibitors of protein deacetylases that regulate pathways of gene expression and protein degradation. the phosphatase inhibitors enhance the effectiveness of cytotoxic anti-cancer drugs in general as well as radiation therapy making them potentially useful for the treatment of many, if not all, cancers in combination with existing standard chemotherapy regimens and the evolving targeted cytotoxic therapies of personalized cancer medicine. the lead compound lb-100 is in phase i trial and has the potential to be first-in-class. the deacetylase in
Organization | Lixte Biotechnology Holdings Inc |
Employees | 3 |
CEO | Mr. Bastiaan van der Baan M.Sc. |
Industry | Biotechnology |
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$1.89
-0.53%
Invesco Bulletshares 2025 Hi
$1.89
-0.53%
Schwab International Dividend Equity Etf
$1.89
-0.53%
Blockchain Coinvestors Acquisition Corp.
$1.89
-0.53%
Allgiant Travel Company
$1.89
-0.53%
Rogers Corp
$1.89
-0.53%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$1.89
-0.53%
Iheartmedia
$1.89
-0.53%
Lightpath Technologies Inc
$1.89
-0.53%